Please login to the form below
New Accounts, October, 2006 - Advertising
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period July to September 2006 inclusive
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period July to September 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email new_accounts@pmlive.com
To submit an entry for New Accounts, email new_accounts@pmlive.com
|
|
|
|
|
|
AstraZeneca |
Symbicort (multimedia) |
Respiratory |
RFA Advertising & Marketing |
|
British Medical Journal |
Clinical Evidence |
N/A |
The Foundry |
|
Eisai/Janssen-Cilag |
Pariet |
Gastrointestinal |
Dewar Alexander |
|
Kogen |
Diclomax |
Arthritis and pain |
Swordfish Advertising |
|
Janssen-Cilag |
Multimedia project |
Migraine |
RFA Advertising & Marketing |
|
Novartis |
Diovan/CoDiovan |
Cardiovascular |
ICC (Lowe Healthcare WW) |
|
Pfizer Consumer Healthcare UK |
Media activity |
OTC and POM portfolio |
Medical Media Services |
|
ProStrakan |
Rapinyl |
Pain management |
Life |
Share
Related Hub content
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Eli Lilly announces $450m investment in US manufacturing site
- World Health Organization releases latest set of COVID-19 guidelines
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- 5 ways we’re enhancing our services to support our clients in 2023
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
- ASH 2022: bad blood but big advances
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Nicki Muir moves from LEC Healthcare to The Purple Agency
- Alzheimer’s Society urges UK government to deliver on dementia plan
- EC launches cancer imaging initiative to accelerate innovation and early diagnosis
- EU outlines measures to mitigate antibiotic shortage across Europe
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
